Joseph Park, PhD, is the senior manager of regulatory strategy and policy at Samsung Bioepis. Park obtained his PhD from the Korea Advanced Institute of Science and Technology.
Confusion Persists Around the Interchangeability Designation for Biosimilars
The legal and common uses of “interchangeability” continue to be conflated.
Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One
As more biosimilars are granted interchangeability status, 2 representatives from Samsung Bioepis stop misinformation in its tracks by clarifying that the designation will primarily impact pharmacy dispensing instead of prescription habits.
2 Clarke Drive Cranbury, NJ 08512